Organon suspends earnings call as Sun Pharma merger proceeds, reports Q3 results

Organon & Co. disclosed on October 30, 2026 that it released its financial results for the quarter ended September 30, 2026 with the filing of its Quarterly Report on Form 10-Q with the SEC.¹ The company noted that because of its pending merger with Sun Pharmaceutical Industries Limited, it has suspended its customary practice of issuing a quarterly earnings press release and hosting an earnings conference call.¹

In place of that release, Organon furnished certain supplemental non-GAAP metrics for the quarter ended September 30, 2026 in Exhibit 99.1 to the Form 8-K.¹

On the financial side, Organon reported GAAP reported net income of $164 million for the three months ended September 30, 2026, versus $160 million a year earlier, and $418 million for the nine months ended September 30, 2026, versus $392 million a year earlier.¹ Adjusted EBITDA for the quarter was $502 million in the third quarter of 2026, compared with $518 million in the same period of 2025, with an Adjusted EBITDA margin of 31.9% versus 32.3%.¹

The filing disclosed costs tied to the pending acquisition: other costs for the third quarter of 2026 included $19 million related to the pending transaction with Sun Pharmaceutical Industries Limited, and nine-month other costs included $30 million related to that transaction plus $17 million tied to an unfavorable resolution of a working capital matter from the Dermavant acquisition.¹

Organon also continued to report costs from winding down manufacturing arrangements with its former parent, noting that manufacturing network related costs include costs from exiting manufacturing and supply agreements with Merck & Co., Inc., Rahway NJ, US.¹ The filing was signed by Chief Financial Officer Matthew Walsh, dated October 30, 2026.¹